Related Experiment Video

Updated: Aug 7, 2026

Intra-Operative Neural Monitoring of Thyroid Surgery in a Porcine Model
08:16

Intra-Operative Neural Monitoring of Thyroid Surgery in a Porcine Model

Published on: February 11, 2019

21.5K

Device profile of the iTind temporary implantable nitinol device for benign prostatic hyperplasia

Levi Godard1, Hersh Trivedi2, Gopal Narang2

  • 1Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

Expert Review of Medical Devices
|June 6, 2025
PubMed
Abstract

Keywords:
Benign prostatic hyperplasiaiTind, temporary implantable nitinol devicelower urinary tract symptomsminimally invasive treatmenturethral stent

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.3K
Author Spotlight: Rapid Prototyping and Testing of Self-Expanding Nitinol Frames for Transcatheter Implantable Devices06:53

Author Spotlight: Rapid Prototyping and Testing of Self-Expanding Nitinol Frames for Transcatheter Implantable Devices

Published on: March 7, 2025

438

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...